Overview
Background
A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.
Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Qualifications
- Bachelor (Honours) of Medicine, University of Zurich
- Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
- Doctoral (Research), University of Zurich
- Professional Doctorate, University of Zurich
- Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists
Research impacts
Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.
Works
Search Professor Simone M Goldinger’s works on UQ eSpace
2016
Journal Article
Noncutaneous Melanomas: A Single-Center Analysis
Del Prete, Valerio, Chaloupka, Karla, Holzmann, David, Fink, Daniel, Levesque, Mitchell, Dummer, Reinhard and Goldinger, Simone M. (2016). Noncutaneous Melanomas: A Single-Center Analysis. Dermatology, 232 (1), 22-29. doi: 10.1159/000441444
2015
Journal Article
Acquired <i>BRAF</i> inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Johnson, Douglas B., Menzies, Alexander M., Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A., Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F., Thompson, John F., Becker, Juergen C., Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M., Pupo, Gulietta M., Hugo, Willy, Kong, Xiangju, Garraway, Levi A., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S., Long, Georgina V. and Schadendorf, Dirk (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51 (18), 2792-2799. doi: 10.1016/j.ejca.2015.08.022
2015
Journal Article
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk and Garraway, Levi A. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350 (6257), 207-211. doi: 10.1126/science.aad0095
2015
Journal Article
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kaehler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard and Goldinger, Simone M. (2015). Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. Plos One, 10 (10) e0139438. doi: 10.1371/journal.pone.0139438
2015
Journal Article
Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma
Matsushita, Shigeto, Kraehenbuehl, Lukas, Otsuka, Atsushi, Mihic-Probst, Daniela, Cheng, Phil, Dummer, Reinhard and Goldinger, Simone M. (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42 (9), 927-928. doi: 10.1111/1346-8138.12964
2015
Journal Article
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F. Stephen, Schachter, Jacob, Pavlick, Anna C., Lewis, Karl D., Cranmer, Lee D., Blank, Christian U., O'Day, Steven J., Ascierto, Paolo A., Salama, April K. S., Margolin, Kim A., Loquai, Carmen, Eigentler, Thomas K., Gangadhar, Tara C., Carlino, Matteo S., Agarwala, Sanjiv S., Moschos, Stergios J., Sosman, Jeffrey A., Goldinger, Simone M., Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M., Wolchok, Jedd D., Eggermont, Alexander ... Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16 (8), 908-918. doi: 10.1016/S1470-2045(15)00083-2
2015
Journal Article
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26 (6), 1238-1244. doi: 10.1093/annonc/mdv139
2015
Conference Publication
Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients. 21st Annual Meeting of the German-Society-for-Radiation-Oncology, Hamburg Germany, Jun 25-28, 2015. MUNICH: URBAN & VOGEL.
2015
Conference Publication
A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma
Goldinger, Simone M., Gobbi, Sharon, Ding, Michelle, Frauchiger, Anna Lisa, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine, Assaf, Chalid and Dummer, Reinhard (2015). A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
2015
Conference Publication
Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients
Goldinger, Simone M., Mangana, Joanna, Frauchiger, Anna L., Kaufmann, Corina, Held, Ulrike, Von Moos, Roger, Romano, Emanuela, Michielin, Olivier, Levesque, Mitchell Paul and Dummer, Reinhard (2015). Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
2015
Conference Publication
Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab
Brueggemann, Caroline, Weide, Benjamin, Goldinger, Simone M., Konrad, Andreas, Erdmann, Michael, Schadendorf, Dirk, Croner, Roland S., Kraehenbuehl, Lukas, Kaehler, Katharina C., Hafner, Christian, Leisgang, Waltraud, Kiesewetter, Franklin, Dummer, Reinhard, Schuler, Gerold, Stuerzl, Michael and Heinzerling, Lucie (2015). Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
2015
Conference Publication
Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial
Kunz, Michael, Urosevic-Maiwald, Mirjana, Cozzio, Antonio, Dippel, Michaela, Dreier, Jil, French, Lars E., Goldinger, Simone, Guenova, Emmanuella, Jenni, Daniella, Kamarachev, Jivko, Mangana, Johanna and Dummer, Reinhard (2015). Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial. NEW YORK: MOSBY-ELSEVIER.
2015
Conference Publication
Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation
Kraehenbuehl, L., Goldinger, S. M., Matsushita, S., Amann, V. C., Kempf, W., Levesque, M. P. and Dummer, R. (2015). Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation. HOBOKEN: WILEY-BLACKWELL.
2015
Journal Article
Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor
Galliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512
2015
Journal Article
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Goldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113
2015
Journal Article
Curing advanced melanoma by 2025
Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168
2015
Journal Article
Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
Cheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4
2014
Journal Article
Basal cell carcinomas in a tertiary referral centre: a systematic analysis
Dreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217
2014
Conference Publication
Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients
Cosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL.
2014
Journal Article
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231
Supervision
Availability
- Associate Professor Simone M Goldinger is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Media
Enquiries
For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team: